NCT06050226View on ClinicalTrials.gov

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

November 28, 2024

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

MY008211A tablets

The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.

Trial Locations (1)

Unknown

Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY